“Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s423. doi:10.25251/skin.8.supp.423.